CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans

Marta Stanzani; Sergio L. R Martins; Rima M Saliba; Lisa S. St John; Susan Bryan; Daniel Couriel; John McMannis; Richard E Champlin; Jeffrey J Molldrem; Krishna V Komanduri

doi:10.1182/blood-2003-06-2085

Back

CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans

Journal article

Peer reviewed

CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans

Marta Stanzani, Sergio L. R Martins, Rima M Saliba, Lisa S. St John, Susan Bryan, Daniel Couriel, John McMannis, Richard E Champlin, Jeffrey J Molldrem and Krishna V Komanduri

Blood, Vol.103(3), pp.1140-1146

2004-02-01

DOI: https://doi.org/10.1182/blood-2003-06-2085

PMID: 12907445

Abstract

AbstractGraft-versus-host disease (GVHD) occurs in an unpredictable fashion after 30% to 50% of matched-related transplantations. The presence of increased frequencies of CD4+CD25+ regulatory T cells in donor grafts has been shown to ameliorate GVHD after allogeneic transplantation in murine models. To determine whether a similar relationship exists in humans, we quantitated the coexpression of CD25 on CD4+ and CD8+ T cells within 60 donor grafts infused into matched siblings and examined GVHD incidence in the respective recipients. Recipients in whom GVHD developed received donor grafts containing significantly higher frequencies of CD4+ T cells coexpressing CD25 than those who did not (median, 9.26% vs 2.22%; P = .004). Frequencies of donor graft CD8+ T cells coexpressing CD25 were also higher (0.65% vs 0.14%; P = .002). Furthermore, transplant recipients who received grafts containing fewer CD4+CD25+ and CD8+CD25+ T cells were less likely to acquire acute GVHD, even though these donor-recipient pairs were similar to others with respect to relevant clinical variables. These data suggest that the coexpression of CD4 and CD25 may be insufficient to identify regulatory T cells in humans and that increased frequencies and numbers of CD25+ T cells in donor grafts is associated with GVHD in transplant recipients. (Blood. 2004;103:1140-1146)

Metrics

15 Record Views

79 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.6 Immunology; 1.6.487 FOXP3
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans
Creators: Marta Stanzani - From the Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston; the Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy; and the Department of Hematology, Fleury-Diagnostic Medical Center, Sao Paolo, Brazil
Sergio L. R Martins - From the Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston; the Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy; and the Department of Hematology, Fleury-Diagnostic Medical Center, Sao Paolo, Brazil
Rima M Saliba - From the Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston; the Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy; and the Department of Hematology, Fleury-Diagnostic Medical Center, Sao Paolo, Brazil
Lisa S. St John - From the Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston; the Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy; and the Department of Hematology, Fleury-Diagnostic Medical Center, Sao Paolo, Brazil
Susan Bryan - From the Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston; the Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy; and the Department of Hematology, Fleury-Diagnostic Medical Center, Sao Paolo, Brazil
Daniel Couriel - From the Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston; the Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy; and the Department of Hematology, Fleury-Diagnostic Medical Center, Sao Paolo, Brazil
John McMannis - From the Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston; the Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy; and the Department of Hematology, Fleury-Diagnostic Medical Center, Sao Paolo, Brazil
Richard E Champlin - From the Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston; the Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy; and the Department of Hematology, Fleury-Diagnostic Medical Center, Sao Paolo, Brazil
Jeffrey J Molldrem - From the Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston; the Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy; and the Department of Hematology, Fleury-Diagnostic Medical Center, Sao Paolo, Brazil
Krishna V Komanduri - From the Transplant Immunology Section, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston; the Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy; and the Department of Hematology, Fleury-Diagnostic Medical Center, Sao Paolo, Brazil
Publication Details: Blood, Vol.103(3), pp.1140-1146
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 12907445
Record Identifier: 991031559104602976